© dkfz.de

The listed publications contain an "Acknowledgement" of the Helmholtz Alliance on Immunotherapy of Cancer (Status October 2010):


1. Arzberger, S., Hosel, M., and Protzer, U. (2010). Apoptosis of hepatitis B virus-infected hepatocytes prevents release of infectious virus. J Virol 84, 11994-12001.

2. Bankwitz, D., Steinmann, E., Bitzegeio, J., Ciesek, S., Friesland, M., Herrmann, E., Zeisel, M. B., Baumert, T. F., Keck, Z. Y., Foung, S. K., Pecheur, E. I., and Pietschmann, T. (2010). Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 84, 5751-5763.

3. Bazhin, A. V., Kahnert, S., Kimpfler, S., Schadendorf, D., and Umansky, V. (2010). Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. Mol Immunol 47, 678-684.

4. Beckhove, P., Warta, R., Lemke, B., Stoycheva, D., Momburg, F., Schnolzer, M., Warnken, U., Schmitz-Winnenthal, H., Ahmadi, R., Dyckhoff, G., Bucur, M., Junger, S., Schueler, T., Lennerz, V., Woelfel, T., Unterberg, A., and Herold-Mende, C. (2010). Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J Clin Invest 120, 2230-2242.

5. Blatner, N. R., Bonertz, A., Beckhove, P., Cheon, E. C., Krantz, S. B., Strouch, M., Weitz, J., Koch, M., Halverson, A. L., Bentrem, D. J., and Khazaie, K. (2010). In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A 107, 6430-6435.

6. Bouwhuis, M. G., Gast, A., Figl, A., Eggermont, A. M., Hemminki, K., Schadendorf, D., and Kumar, R. (2010). Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol Immunother. 59(2): 303-312.

7. Braun, M., ter Meer, D., Müller, B., Raffegerst, S., Simm, B., Wilde, S., Spranger, S., Ellwart, J., Mosetter, B., Schendel, D.J., and C.S. Falk. (2010). The CD6 scavenger receptor is differentially expressed on a CD56dim NK cell subpopulation and contributes to NK-derived cytokine and chemokine secretion. Journal of Innate Immunity in press.

8. Briesemeister, D., Sommermeyer, D., Loddenkemper, C., Loew, R., Uckert, W., Blankenstein, T., and Kammertoens, T. (2010). Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer (DOI: 10.1002/ijc.25350).

9. Brill, T. H., Kubler, H. R., Pohla, H., Buchner, A., Fend, F., Schuster, T., van Randenborgh, H., Paul, R., Kummer, T., Plank, C., Eisele, B., Breul, J., Hartung, R., Schendel, D. J., and Gansbacher, B. (2009). Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther 20, 1641-1651.

10. Buchner, A., Pohla, H., Willimsky, G., Frankenberger, B., Frank, R., Baur-Melnyk, A., Siebels, M., Stief, C. G., Hofstetter, A., Kopp, J., Pezzutto, A., Blankenstein, T., Oberneder, R., and Schendel, D. J. (2010). Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther 21, 285-297.

11. Burdek, M., Spranger, S., Wilde, S., Frankenberger, B., Schendel, D. J., and Geiger, C. (2010). Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med 8, 90.
12. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme, C., Lahlou, N., Lefrere, F., Blanche, S., Audit, M., Payen, E., Leboulch, P., l'Homme, B., Bougneres, P., von Kalle, C., Fischer, A., Cavazzana-Calvo, M., and Aubourg, P. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.

13. Ciesek, S., Steinmann, E., Iken, M., Ott, M., Helfritz, F. A., Wappler, I., Manns, M. P., Wedemeyer, H., and Pietschmann, T. (2010). Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 138, 1875-1884.

14. Ciesek, S., Steinmann, E., Wedemeyer, H., Manns, M. P., Neyts, J., Tautz, N., Madan, V., Bartenschlager, R., von Hahn, T., and Pietschmann, T. (2009). Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 50, 1638-1645.

15. Disis, M. L., Bernhard, H., and Jaffee, E. M. (2009). Use of tumour-responsive T cells as cancer treatment. Lancet 373, 673-683.

16. Gabriel, R., Eckenberg, R., Paruzynski, A., Bartholomae, C. C., Nowrouzi, A., Arens, A., Howe, S. J., Recchia, A., Cattoglio, C., Wang, W., Faber, K., Schwarzwaelder, K., Kirsten, R., Deichmann, A., Ball, C. R., Balaggan, K. S., Yanez-Munoz, R. J., Ali, R. R., Gaspar, H. B., Biasco, L., Aiuti, A., Cesana, D., Montini, E., Naldini, L., Cohen-Haguenauer, O., Mavilio, F., Thrasher, A. J., Glimm, H., von Kalle, C., Saurin, W., and Schmidt, M. (2009). Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 15, 1431-1436.

17. Gagiannis, S., Müller, M., Uhlemann, S., Koch, A., Melino, G., Krammer, P. H., Nawroth, P. P., Brune, M., and Schilling, T. (2009). Parathyroid hormone-related protein confers chemoresistance by blocking apoptosis signaling via death receptors and mitochondria. Int J Cancer 125, 1551-1557.

18. Gast, A., Scherer, D., Chen, B., Bloethner, S., Melchert, S., Sucker, A., Hemminki, K., Schadendorf, D., and Kumar, R. (2010). Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 49, 733-745.

19. Geiger, C., Nossner, E., Frankenberger, B., Falk, C. S., Pohla, H., and Schendel, D. J. (2009). Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J Mol Med 87, 595-612.

20. Gogas, H., Kirkwood, J. M., Falk, C. S., Dafni, U., Sondak, V. K., Tsoutsos, D., Stratigos, A., Markopoulos, C., Pectasides, D., and Spyropoulou-Vlachou, M. (2010). Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 116, 4326-4333.

21. Halama, N., Braun, M., Kahlert, C., Spille, A., Quack, C., Rahbari, N., Koch, M., Weitz, J., Zoernig, I., Schirmacher, P., Brand, K., Grabe, N., and C.S. Falk. (2010) Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines & cytokines. Clin. Cancer Res. in press.

22. Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., and Korangy, F. (2009). Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799-807.

23. Hoffmann, S. C., Wabnitz, G. H., Samstag, Y., Moldenhauer, G., and Ludwig, T. (2010). Functional analysis of bispecific antibody (EpCAMxCD3)-mediated T-lymphocyte and cancer cell interaction by single-cell force spectroscopy. Int J Cancer. (DOI: 10.1002/ijc.25556)

24. Hosel, M., Quasdorff, M., Wiegmann, K., Webb, D., Zedler, U., Broxtermann, M., Tedjokusumo, R., Esser, K., Arzberger, S., Kirschning, C. J., Langenkamp, A., Falk, C., Buning, H., Rose-John, S., and Protzer, U. (2009). Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50, 1773-1782.

25. John von Freyend, M., Untergasser, A., Arzberger, S., Oberwinkler, H., Drebber, U., Schirmacher, P., and Protzer, U. (2010). Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. J Viral Hepat in press.

26. Johnson, T. S., Mahnke, K., Storn, V., Schonfeld, K., Ring, S., Nettelbeck, D. M., Haisma, H. J., Le Gall, F., Kontermann, R. E., and Enk, A. H. (2008). Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 14, 8169-8177.

27. Kammertoens, T., and Blankenstein, T. (2009). Making and circumventing tolerance to cancer. Eur J Immunol 39, 2345-2353.

28. Karakhanova, S., Meisel, S., Ring, S., Mahnke, K., and Enk, A. H. (2010). ERK/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets. Eur J Immunol 40, 254-266.

29. Kieback, E., and Uckert, W. (2010). Enhanced T cell receptor gene therapy for cancer. Expert Opin Biol Ther 10, 749-762.

30. Kiessling, M. K., Klemke, C. D., Kaminski, M. M., Galani, I. E., Krammer, P. H., and Gulow, K. (2009). Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 69, 2365-2374.

31. Kimpfler, S., Sevko, A., Ring, S., Falk, C., Osen, W., Frank, K., Kato, M., Mahnke, K., Schadendorf, D., and Umansky, V. (2009). Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 183, 6330-6337.

32. Klemke, C. D., Brenner, D., Weiss, E. M., Schmidt, M., Leverkus, M., Gulow, K., and Krammer, P. H. (2009). Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res 69, 4175-4183.

33. Kronig, H., Hofer, K., Conrad, H., Guilaume, P., Müller, J., Schiemann, M., Lennerz, V., Cosma, A., Peschel, C., Busch, D. H., Romero, P., and Bernhard, H. (2009). Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 125, 649-655.

34. Leisegang, M., S. Wilde, S. Milosevic, S. Spranger, B. Frankenberger, W. Uckert*, D. J. Schendel*. (2010). MHC-restricted fratricide of recipient lymphocytes expressing transgenic T cell receptors specific for the apoptosis-inhibitor protein survivin. J Clin Invest doi: 10., 72/JCI43437 (*equal contribution).

35. Leisegang, M., Turqueti-Neves, A., Engels, B., Blankenstein, T., Schendel, D. J., Uckert, W., and Noessner, E. (2010). T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res 16, 2333-2343.

36. Li, L. P., Lampert, J. C., Chen, X., Leitao, C., Popovic, J., Müller, W., and Blankenstein, T. (2010). Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 16, 1029-1034.

37. Malz, M., Weber, A., Singer, S., Riehmer, V., Bissinger, M., Riener, M. O., Longerich, T., Soll, C., Vogel, A., Angel, P., Schirmacher, P., and Breuhahn, K. (2009). Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50, 1130-1139.

38. Meyerhuber, P., Conrad, H., Starck, L., Leisegang, M., Busch, D. H., Uckert, W., and Bernhard, H. (2010). Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes. J Mol Med 88, 1113-1121.

39. Moosmann, A., Bigalke, I., Tischer, J., Schirrmann, L., Kasten, J., Tippmer, S., Leeping, M., Prevalsek, D., Jaeger, G., Ledderose, G., Mautner, J., Hammerschmidt, W., Schendel, D. J., and Kolb, H. J. (2010). Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115, 2960-2970.

40. Müller, M., Gagiannis, S., Nawroth, P. P., Brune, M., and Schilling, T. (2009). Activation of the receptor for parathyroid hormone and parathyroid hormone related protein induces apoptosis via the extrinsic and intrinsic signaling pathway. Int J Mol Med 24, 373-380.

41. Mundt, H. M., Stremmel, W., Melino, G., Krammer, P. H., Schilling, T., and Müller, M. (2010). Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun.

42. Paruzynski, A., Arens, A., Gabriel, R., Bartholomae, C. C., Scholz, S., Wang, W., Wolf, S., Glimm, H., Schmidt, M., and von Kalle, C. (2010). Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 5, 1379-1395.

43. Paschen, A., Sucker, A., Hill, B., Moll, I., Zapatka, M., Nguyen, X. D., Sim, G. C., Gutmann, I., Hassel, J., Becker, J. C., Steinle, A., Schadendorf, D., and Ugurel, S. (2009). Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15, 5208-5215.

44. Protzer, U., Abken, H. (2010). Can engineered "designer" T cells out-smart chronic hepatitis B? . Hepatitis Research and Treatment Article ID 901216.

45. Raffegerst, S. H., Hoelzlwimmer, G., Kunder, S., Mysliwietz, J., Quintanilla-Martinez, L., and Schendel, D. J. (2009). Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice. PLoS One 4, e8539.

46. Ring, S., Karakhanova, S., Johnson, T., Enk, A. H., and Mahnke, K. (2010). Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells. J Allergy Clin Immunol 125, 237-246 e231-237.

47. Ring, S., Oliver, S. J., Cronstein, B. N., Enk, A. H., and Mahnke, K. (2009). CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J Allergy Clin Immunol 123, 1287-1296 e1282.

48. Schilling, T., Kairat, A., Melino, G., Krammer, P. H., Stremmel, W., Oren, M., and Müller, M. (2010). Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. Biochem Biophys Res Commun 394, 817-823.

49. Schilling, T., Schleithoff, E. S., Kairat, A., Melino, G., Stremmel, W., Oren, M., Krammer, P. H., and Müller, M. (2009). Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem Biophys Res Commun 387, 399-404.

50. Schub, A., Schuster, I. G., Hammerschmidt, W., and Moosmann, A. (2009). CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol 183, 6819-6830.

51. Schuster, A., Schilling, T., De Laurenzi, V., Koch, A. F., Seitz, S., Staib, F., Teufel, A., Thorgeirsson, S. S., Galle, P. R., Melino, G., Stremmel, W., Krammer, P. H., and Müller, M. (2010). DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 9 (in press).

52. Seitz, S. J., Schleithoff, E. S., Koch, A., Schuster, A., Teufel, A., Staib, F., Stremmel, W., Melino, G., Krammer, P. H., Schilling, T., and Müller, M. (2010). Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 126, 2049-2066.

53. Sers, C., Kuner, R., Falk, C. S., Lund, P., Sueltmann, H., Braun, M., Buness, A., Ruschhaupt, M., Conrad, J., Mang-Fatehi, S., Stelniec, I., Krapfenbauer, U., Poustka, A., and Schafer, R. (2009). Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 125, 1626-1639.

54. Singer, S., Malz, M., Herpel, E., Warth, A., Bissinger, M., Keith, M., Muley, T., Meister, M., Hoffmann, H., Penzel, R., Gdynia, G., Ehemann, V., Schnabel, P. A., Kuner, R., Huber, P., Schirmacher, P., and Breuhahn, K. (2009). Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 69, 2234-2243.

55. Sommermeyer, D., and Uckert, W. (2010). Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 184, 6223-6231.

56. Spranger, S., Javorovic, M., Burdek, M., Wilde, S., Mosetter, B., Tippmer, S., Bigalke, I., Geiger, C., Schendel, D. J., and Frankenberger, B. (2010). Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 185, 738-747.

57. Stabenow, D., Frings, M., Truck, C., Gartner, K., Forster, I., Kurts, C., Tuting, T., Odenthal, M., Dienes, H. P., Cederbrant, K., Protzer, U., and Knolle, P. A. (2010). Bioluminescence imaging allows measuring CD8 T cell function in the liver. Hepatology 51, 1430-1437.

58. Suffner, J., Hochweller, K., Kuhnle, M. C., Li, X., Kroczek, R. A., Garbi, N., and Hammerling, G. J. (2010). Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J Immunol 184, 1810-1820.

59. Voss, R. H., Thomas, S., Pfirschke, C., Hauptrock, B., Klobuch, S., Kuball, J., Grabowski, M., Engel, R., Guillaume, P., Romero, P., Huber, C., Beckhove, P., and Theobald, M. (2010). Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. Blood 115, 5154-5163.

60. Westermann, J., Flörcken, A., Willimsky, G., van Lessen, A., Kopp, J., Takvorian, A., Jöhrens, K., Lukowsky, A., Schönemann, C., Sawitzki, B., Pohla, H., Frank, R., Dörken, B., Schendel, D.J., Blankenstein, T., Pezzutto, A. (2010). Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer – a clinical phase-I study. Gene Therapy (in press).

61. Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D. H., and Schendel, D. J. (2009). Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 114, 2131-2139.

62. Wolterink, S., Moldenhauer, G., Fogel, M., Kiefel, H., Pfeifer, M., Luttgau, S., Gouveia, R., Costa, J., Endell, J., Moebius, U., and Altevogt, P. (2010). Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res 70, 2504-2515.

63. Zhao, F., Falk, C., Osen, W., Kato, M., Schadendorf, D., and Umansky, V. (2009). Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 15, 4382-4390.

64. Zhu, J. Y., Giaisi, M., Kohler, R., Müller, W. W., Muhleisen, A., Proksch, P., Krammer, P. H., and Li-Weber, M. (2009). Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ 16, 1289-1299.